Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma

To evaluate the real-world efficacy and safety of golidocitinib in patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL).

Clinical data of 3 patients with R/R PTCL treated with golidocitinib at our center between May 2024 and November 2025 were retrospectively analyzed. Baseline features, treatment regimens, responses, and adverse events (AEs) were collected and assessed.

Pathological subtypes included PTCL-not otherwise specified (PTCL-NOS, n=2) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, n=1). Following golidocitinib-based therapy, 2 patients achieved complete response (CR) and 1 partial response (PR), yielding an objective response rate (ORR) of 100%. Median follow-up was 6.2 months (range: 4.2-9.1 months); median progression-free survival (PFS) was not reached. Treatment-related AEs were predominantly hematological, mostly grade 1-2 and manageable. No treatment-related deaths occurred.

Golidocitinib exhibits promising efficacy and a tolerable safety profile in R/R PTCL, including rare subtypes, supporting its role as a valuable therapeutic option. Larger cohorts are needed for further validation.